Login
Navigate Fool.com
Will DRRX beat
the market?

DURECT Corp

NASDAQ: DRRX

Community Rating: 2 Stars: Unattractive

1.31 0.02 (1.55%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.28
Previous Close $1.29
Daily Range $1.26 - $1.31
52-Week Range $0.76 - $2.69
Market Cap $144.7M
P/E Ratio -6.14
Dividend (Yield) $0.00 (0.0%)
Volume 248,785
Average Daily Volume 679,164
Current FY EPS -$0.19

How do you think DRRX
will perform against the market?

Top DRRX Bull/Bear Pitches

 

hackwojr (< 20)
Submitted August 19, 2006

Durect has several products in phase II trials that will really be excellent for the treament of post operative pain. Striker, a company that would compete with Durect just purchased something like 1 … More

0 Replies Reply Report this Post
 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

America's Top 5 Health Threats in 2014

There are 12,420 diseases, disorders, and ailments according to W.H.O., but these are the five health risks most concerning to the CDC in 2014.

This Week in Biotech: Three Strikes and You're Out!

The FDA and its advisory panel give a thumbs down to three experimental drugs, while buyout mania strikes the biotech sector.

Why DURECT Corporation Shares Were Walloped

DURECT shares dropped significantly after it's told "Do not pass go" by the FDA for its surgical painkiller, posidur.

This Is America's Fastest-Growing Drug Problem

America's fastest-growing drug problem isn't what you might think. Find out how we're fighting this dangerous problem.

Market Wrap for Friday, August 16: Pullback In Equities Continues To Close Week

Healthcare Stocks Falling Near Close; Pain Therapeutics Soars After Pfizer Restarts Trial of New Pai

Healthcare Stocks Falling Near Close; Pain Therapeutics Soars After Pfizer Restarts Trial of New Pain-Killer

Top Biotech Stocks to Buy and Stocks to Short from PropThink

Healthcare Sector Down 2%; Durect Surges After FDA Accepts Prospective Post-Op Pain-Reliever For Rev

Healthcare Sector Down 2%; Durect Surges After FDA Accepts Prospective Post-Op Pain-Reliever For Review

Sector Update: Healthcare

Thursday’s movers: Durect Corp., Solta Medical

See More DRRX News...

Sector

Healthcare

Industry

Drugs

DURECT Corp (DRRX) Description

The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies. Website: http://www.durect.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks